Clinical characteristics and outcomes in patients with type 2 diabetes adding insulin glargine to exenatide or exenatide to insulin glargine in a US managed care setting

被引：0
|
作者：
Levin, P. [1 ]
Wei, W. [2 ]
Wang, L. [3 ]
Baser, O. [3 ]
机构：
[1] Model Clin Res, Baltimore, MD USA
[2] Sanofi Aventis US, Bridgewater, MA USA
[3] STATinMED Res, Ann Arbor, MI USA
来源：
DIABETOLOGIA | 2011年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1030
引用
收藏
页码：S419 / S419
页数：1
相关论文
共 50 条
  • [1] Clinical Characteristics and Outcomes in Patients with Type 2 Diabetes (T2D) Adding Insulin Glargine to Exenatide or Exenatide to Insulin Glargine in a US Managed Care Setting
    Levin, Philip
    Wei, Wenhui
    Wang, Li
    Damon, Douglas
    Baser, Onur
    DIABETES, 2011, 60 : A266 - A266
  • [2] Glycemic Outcomes Following Initiation of Insulin Glargine or Exenatide in Patients with Type 2 Diabetes
    Rosenstock, Julio
    Daine, Marie-Paule
    Bhushan, Madhu
    Bhushan, Rajat
    Home, Philip
    DIABETES, 2009, 58 : A137 - A138
  • [3] Real-world characteristics of patients with type 2 diabetes initiating insulin glargine plus exenatide or insulin glargine plus liraglutide
    Di Genio, A.
    Ling, Z.
    Davis, K. L.
    Meyers, J. L.
    Dalal, M. R.
    DIABETOLOGIA, 2012, 55 : S328 - S328
  • [4] REAL-WORLD' CLINICAL OUTCOMES OF EXENATIDE BID COMPARED TO INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES
    Pawaskar, M.
    Li, Q.
    Hoogwerf, B.
    Reynolds, M. W.
    Faries, D. E.
    Bruhn, D.
    Bergenstal, R.
    VALUE IN HEALTH, 2011, 14 (07) : A475 - A475
  • [5] Exenatide or insulin glargine for suboptimally controlled diabetes?
    Heine, RJ
    Van Gaal, LF
    Johns, D
    Mihm, MJ
    Widet, MH
    Brodows, RG
    ANNALS OF INTERNAL MEDICINE, 2005, 143 (08) : I30 - I30
  • [6] Glycaemic outcomes following initiation of insulin glargine or exenatide in type 2 diabetes patients treated with oral agents in US
    Bhushan, R.
    Rosenstock, J.
    Dain, M. -P.
    Bhushan, M.
    Home, P.
    DIABETOLOGIA, 2009, 52 : S293 - S293
  • [7] Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes
    Levin, Philip
    Wei, Wenhui
    Wang, Li
    Pan, Chunshen
    Douglas, Damon
    Baser, Onur
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (03) : 439 - 446
  • [8] Medication compliance and persistency in patients with type 2 diabetes initiating exenatide or insulin glargine
    Fabunmi, Rosalind
    Nielsen, Loretta
    Wade, Rolin L.
    Quimbo, Ralph
    Schroeder, Brock
    Massoudi, Marjan
    Misurski, Derek A.
    Wintle, Matthew
    DIABETES, 2008, 57 : A346 - A346
  • [9] Exenatide and insulin glargine are equally effective in patients with suboptimally controlled type 2 diabetes
    Lofthouse M.
    Nature Clinical Practice Endocrinology & Metabolism, 2006, 2 (1): : 7 - 7
  • [10] Medication compliance and persistency in patients with type 2 diabetes initiating exenatide or insulin glargine
    Fabunmi, R.
    Nielsen, L.
    Wade, R.
    Quimbo, R.
    Schroeder, B.
    Massoudi, M.
    Misurski, D.
    Wintle, M.
    DIABETOLOGIA, 2008, 51 : S352 - S352
12345